Stockreport

Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne [Yahoo! Finance]

Dermata Therapeutics, Inc.  (DRMA) 
PDF - Phase 2b for DMT310 achieved statistically significant results for all primary endpoints - SAN DIEGO, CA / ACCESSWIRE / December 3, 2024 / Dermata Therapeutics, Inc [Read more]